drugset / Trial / NCT02117297
SCT Plus Immune Therapy in Average Risk AML/MDS
NaSingle-groupOpen-labelTreatment
Summary
Allogeneic stem cell transplantation followed by targeted immune therapy with Gemtuzumab Ozogamicin (Mylotarg) will be given to patients with average risk AML or MDS.
Timeline
- Start
- 2012-01-12
- Primary completion
- 2023-03-30
- Completion
- 2023-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemtuzumab Ozogamicin | Monoclonal antibody | 9 mg/m2 | Intravenous |